. A key role of the gut microbiota in the patho genesis of IBD has long been postulated; however, definitive causeeffect mechanistic relationships have been challenging to prove outside of specific animal models. In particular, IBD has been associated with dysbiosis, defined as a decrease in gut microbial diversity owing to a shift in the balance between commensal and potentially pathogenic microorganisms [4] [5] [6] [7] . Indeed, the clinical observation that IBD can respond to antibiotic treatment is consistent with the idea that intestinal bacteria contribute to the inflammatory response 8, 9 . Other observations supporting a role for the gut microbiota in IBD include the predisposition of inflammation for anatomical regions with relative faecal stasis (terminal ileum and rectum), the effectiveness of faecal diversion as a treatment for Crohn's disease [10] [11] [12] , and the rapidly increasing incidence of IBD globally associated with industrialization and accompanying alterations in diet and environmental exposures 13, 14 . Although these associations are consistent with a role of the gut microbiota in IBD pathogenesis, the precise role of dysbiosis is less clear. Studies attempting to determine whether dysbiosis is truly causative or merely a consequence of inflammation have suffered from a number of limitations, making it difficult to draw definitive conclusions (BOX 1) . In this Review, we will describe current associations between IBD and dysbiosis, the role of the gut microbiota in the context of specific animal models, and the potential clinical translation of microbiota-centered therapeutic approaches for human IBD.
Microbiota composition and IBD
Multiple studies have documented differences in the composition of the gut microbiota between patients with IBD and healthy individuals, particularly with respect to microbial diversity and the relative abundance of specific bacterial taxa. Both expansion of potential pathogens and global changes in composition (that is, increased or decreased abundance of indicator species) have been described. For example, the phylum Firmicutes -specifically Faecailbacterium prausnitzii -is often reduced in proportional abundance in the stool of patients with Crohn's disease 7, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , although studies focused on mucosal biopsies have questioned this association 25, 26 . Conversely, members of the Proteobacteria phylum, such as Enterobacteriaceae 27, 28 , including Escherichia coli 19, 29, 30 , are commonly increased in patients with IBD relative to healthy individuals. Differences in the composition of the gut microbiota have been documented even between members of the same family (including twins) who are discordant for IBD 31, 32 , suggesting that dys biosis is primarily associated with disease state rather than environmental or genetic factors. Such cross-sectional studies do not provide information about the timing of dysbiosis relative to disease onset and, therefore, should be interpreted with caution particularly with regards to causeeffect relationships. For example, mucosal biopsies from twin pairs discordant for ulcerative colitis have shown a reduction in gut microbiota diversity in both siblings relative to unrelated healthy individuals, but the changes were more pronounced in the affected twin 33 . However, as the unaffected twins were not followed prospectively, it is not clear whether these findings reflected the gradual development of dysbiosis before the onset of IBD or, on the contrary, a lack of association between dysbiosis and clinical disease.
Studies of paediatric cohorts have attempted to address the temporal relationship between dysbiosis and inflammmation. Although there has been debate over the degree of dysbiosis in paediatric patients, particularly at the mucosal level, most studies have shown substantial differences between diseased and healthy individuals 34, 35 . Thus, dysbiotic changes were described in stool and mucosal biopsies from newly diagnosed, treatmentnaive children with Crohn's disease, suggesting that dysbiosis might precede clinical disease and develop independently of long-standing inflammation and/or medical therapy 36 . A prospective study of paediatric patients with Crohn's disease similarly concluded that dysbiosis reflected the presence and severity of inflammation; however, this study also found an independent association between dysbiosis and other factors such as diet and the use of antibiotics 37 . Thus, while changes in the gut microbiota might occur early in IBD and perhaps contribute to the onset of disease, over time environmental factors, including inflammation itself, probably further contribute to dysbiosis by altering the metabolic conditions in the gut (discussed later).
Although global changes in the microbiota of patients with IBD have been documented, strong evidence for the existence of specific pathobionts -commensal microorganisms that, under specific environmental or genetic influences, can cause IBD 38 -is limited. Enterobacteriaceae, and in particular certain strains of adherent-invasive E. coli (AIEC), have been associated with the ileal mucosa of patients with Crohn's disease 39 and have been proposed as potential pathobionts based on their ability replicate in epithelial cells in vitro 40 . Mycobacterium avium subsp. paratuberculosis has also been investigated as a potential cause of Crohn's disease owing to its ability to cause chronic granulo matous enteritis in sheep and cattle [41] [42] [43] [44] ; however, clinical studies have not borne out this hypothesis 45, 46 . Similarly, a specific association between Fusobacterium nucleatum, ulcerative colitis and the development of colorectal cancer has been proposed based on the isolation of a highly invasive strain from patients with ulcerative colitis, but a clear cause-and-effect relationship has not been proven 47, 48 . Pathobionts probably act in concert with the rest of the gut microbiota to cause disease, rather than as individual infectious agents, a possibility supported by observations in animal models (discussed later).
Although it is tempting to postulate an inciting role of the microbiota in IBD pathogenesis, it should be emphasized that the studies discussed so far describe associations and do not prove causation. In fact, evidence suggests that dysbiosis in IBD might, in large part, reflect the response of a complex microbial community to the environmental stress of intestinal inflammation. In the healthy gastrointestinal tract a radial oxygen gradient exists due to the diffusion of oxygen from the host mucosa into the gut lumen [49] [50] [51] . Accordingly, bacteria adherent to the colonic mucosa have higher oxygen tolerance and cata lase expression relative to faeces-associated species 51 . As inflammation is an oxid ative state, it might be expected to promote the outgrowth of aerotolerant taxa such as Proteobacteria and Actinobacteria. Indeed, the mouse pathogen Citrobacter rodentium has been shown to gain a fitness advantage by promoting epithelial aerobic respiration and increasing oxygenation of the mucosal surface 52 . Alternatively, several lines of evidence have shown that intestinal inflammation induces the production of small molecules that serve as terminal electron acceptors for facultative anaerobes such as Enterobacteriaceae 37, 53 . Thus, metabolic alterations associ ated with inflammation and/or pathobiont coloniza tion might act as microbial stressors and promote the outgrowth of dysbiotic species.
The nonbacterial microbiota and IBD The virome and IBD. To date, most studies investigating the link between inflammation and the microbiota have focused on bacteria. However, the microbiome also includes fungi and viruses, and the role of these microorganisms in health and disease is being increasingly appreciated. Shotgun metagenomic analyses of viral particles isolated from faecal samples have shown that the gut virome is composed predominantly of bacteriophages [54] [55] [56] . Changes in bacteriophage composition associated with IBD have been described, most notably an increase in Caudovirales bacteriophage sequences in ileal biopsy samples and intestinal washes from paediatric patients with Crohn's disease 57, 58 . Importantly, expansion of Caudovirales bacteriophages was associated with a reduction in bacterial diversity. Through their diverse effects on bacteria -ranging from cell lysis to the transfer of genetic material encoding toxins or antibiotic resistance -phages can confer differential fitness on their
Key points
• Alterations in intestinal microbial composition have long been associated with chronic inflammation; however, a definitive cause-effect relationship between dysbiosis and IBD has been difficult to prove, especially in humans • Dysbiosis alters not only the composition of the intestinal microbiota, but also its metabolome, thereby exerting a wide range of effects on the host • While the microbiota plays a key pathogenic role in IBD, chronic inflammation, in turn, promotes dysbiosis by altering the oxidative and metabolic environment of the gut • Animal studies have elucidated key immunological pathways in the pathogenesis of IBD, established both pro-inflammatory and anti-inflammatory roles of the gut microbiota, and shown that the gut microbiota is indispensable for pathogenesis in most colitis models • Microbial-based treatments will likely have a role in the future management of IBD; however, many questions remain regarding the bacterial composition, timing of administration, and patient selection for such therapies hosts and influence the microbial composition of the gut (FIG. 1 61, 62 . Fungal sequences can now be identified via culture-independent methods by PCR amplification of the small 18S ribosomal subunit or the internal transcribed spacer region 62, 63 , allowing for more comprehensive assessment of the mycobiome in health and disease.
A study of the stool-associated mycobiome showed an overall increased representation of fungi in paediatric patients with Crohn's disease compared with healthy individuals, however the same five taxa accounted for the majority of fungi in both groups 37 . Moreover, success ful therapy was associated with partial resolution of bacterial dysbiosis but did not lead to reduction in fungal colonization, putting into question the causative role of fungi in inflammation. Indeed, antibiotic treatment, which is commonly used in Crohn's disease, was indepen dently associated with expansion of the same fungal taxa 37 . On the other hand, a study of adults with IBD did show differences in the relative abundance of specific fungi between patients with IBD and healthy controls 64 . Specifically, fungal dysbiosis in IBD was associated with an increased Basidiomycota:Ascomycota ratio, a decreased proportion of Saccharomyces cerevisiae, and an increased abundance of Candida albicans. This study further suggested that the inflammatory environment of Crohn's disease favours the expansion of fungi over bacteria (FIG. 1) . Such a conclusion, however, should be interpreted with caution given the multiple confounders inherent in human research
.
Studies of the mucosa-associated fungal composition have yielded similarly varied results. One study found that overall fungal diversity was higher in patients with IBD relative to healthy individuals, with several species detected only in Crohn's disease or ulcerative colitis samples, although no consistent pattern could be discerned 65 . This study also showed substantial differences in the fungal composition of stool and mucosal samples. Another study of paediatric patients failed to show statistically significant changes in the mycobiome of patients with Crohn's disease relative to healthy individuals, except for enrichment of the genus Malassezia which varied by geographical location 35 . The relative abundance of Basidiomycota and Ascomycota has also been examined in mucosal samples. In a study of paediatric patients, the Basidiomycota:Ascomycota ratio was found to be increased in Crohn's disease compared with healthy individ uals, similar to the findings above for stool 66 . On the other hand, in another study of adults with Crohn's disease, no discernible pattern with regards to these two phyla was seen 67 . Mechanistically, the involvement of fungi in IBD pathogenesis is plausible as a number of IBD susceptibility genes in mice and humans are involved in antifungal immune responses (for example, CARD9, CLEC7A and RELA) 68 . Mice lacking dectin-1 (encoded by Clec7a), the innate immune receptor that recognizes β-glucans in the fungal cell wall, have increased susceptibility to dextran sodium sulfate (DSS) colitis due to the expansion of opportunistic pathogenic fungi 69 . Similarly, Card9 −/− mice have altered bacterial and fungal microbiota that cannot metabolize tryptophan into ligands for the aryl hydrocarbon receptor and, therefore, fail to upregulate IL-22, which is necessary for recovery from colitis 70 . More recently, S. cerevisiae colonization was shown to promote purine metabolism in mice, leading to elevated levels of uric acid, which has direct pro-inflammatory properties 71 . Conversely, a protective role for the normal gut mycobiome (including Malassezia spp. and C. albicans) has also been postulated. For example, prolonged treatment of mice with the antifungal agent fluconazole leads to fungal dysbiosis characterized by the expansion of opportunistic species including Aspergillus amstelodami, Epicoccum nigrum, and Wallemia sebi. Mice enriched for these fungal organisms have worse outcomes of both DSS-associated and T-cell-transfer-mediated colitis with increased numbers of IFNγ and IL-17-secreting CD4 + T cells in the intestine 72 . Collectively, these animal models suggest that fungi might influence intestinal health and disease by suppressing the outgrowth of potential pathobionts, promoting immunoregulatory pathways, and modulating host metabolism. However, as illustrated by the human studies discussed earlier, establishing a direct causal relation ship between specific fungal species and health and disease remains challenging.
Microbial metabolites and IBD
Changes in the the composition of the gut microbiota lead to metabolite alterations that are likely to have a role in IBD pathogenesis. Through metabolomics, correlations between microbial composition and specific 
Bile acids
Steroid acids found in bile that aid in fat emulsification and nutrient digestion.
Short-chain fatty acids
Fatty acids with less than 6 carbons produced by bacterial fermentation of dietary carbohydrates.
Immunoglobulin A (IgA). The most abundant antibody type, mostly associated with mucosal surfaces.
bacterial metabolic pathways can be established and the effects of small molecule (<1,500 Da) products on IBD pathogenesis assessed 73 . When the gut micro biota of healthy individuals and patients with IBD were compared, 12% of metabolic pathways were markedly different, compared with just 2% of genus-level clades 74 . Specifically, amino acid biosynthesis and carbohydrate metabolism pathways were reduced in the IBD microbiome in favour of nutrient uptake, virulence and secretion pathways. Moreover, expression of genes related to oxid ative stress, such as glutathione and sulfate transport, were increased 74 . These findings likely reflect the microbial response to the inflammatory intestinal environ ment of IBD and suggest that functional, rather than compositional, differences might be more informative when studying dysbiosis.
The microbial production of metabolites might affect the host in other ways that are relevant to IBD pathogenesis. For example, bile acid signalling via the nuclear farnesoid-activated X receptor (FXR, also known as bile acid receptor) has been shown to be protective in DSS and 2,4,6-trinitrobenzenesulfonic acid models of colitis by inhibiting NF-κB signalling 75 . As bile salt hydrolases (BSH) in intestinal bacteria play a key part in bile acid modification, dysbiosis could have a direct effect on FXR signalling. Indeed, in silico analysis showed that the relative abundance of BSH in the gut microbiota was markedly reduced in patients with IBD compared with healthy individuals, and this reduction was most evident among Firmicutes from patients with Crohn's disease 76 . Consistent with these findings, levels of secondary bile acids are decreased in patients with IBD, particularly during flares 77 . Collectively, these data are consistent with a model in which impaired microbial enzymatic activity in IBD leads to altered bile salt metabolism and loss of anti-inflammatory signalling through FXR.
Another bacterial metabolic pathway with relevance to IBD is the production of short-chain fatty acids (SCFAs) through the fermentation of undigestable carbohydrates. SCFAs produced by specific clades of Clostridia spp. have been shown to augment regulatory T (T reg )-cell function in the intestinal mucosa through the activation of G protein-coupled receptors as well as via epigenetic effects leading to inhibition of histone deacetylase 78 . This process promotes restoration of immune tolerance and reduces inflammation in mouse models of colitis and asthma 78, 79 . Efforts to target these pathways, either by altering the gut microbiota or through novel small molecule drugs are currently underway.
Host mucosal immune system: animal models As discussed earlier, the gastrointestinal tract is populated by trillions of microorganisms that normally have a commensal or mutualistic relationship with their host. This healthy coexistence is maintained by a variety of immune mechanisms including secretion of mucus, immunoglobulin A (IgA), and antimicrobial peptides that shape the gut microbiota and prevent direct contact with the epithelium 80 . Conversely, the intestinal microbiota influences immune function in both health and disease. For example, germ-free mice have impaired immune development 81 and epithelial repair 82 , while treatment with oral antibiotics can worsen the outcome of viral infections in mice 83 . In humans, the use of antibiotics in early childhood has been associated with increased risk of Crohn's disease, suggesting the microbiota might help set the threshold for immune activation versus tolerance 84 . Alternatively, antibiotics can potentiate the expansion of pathobionts such as Clostridium difficile, which is best managed by restoring intestinal microbial diversity using faecal microbiota transplantation 85 . Thus, the micro biota suppresses pathogens, promotes immune tolerance, initiates epithelial repair, and ensures the development of balanced immune cell subsets.
The healthy relationship between host and gut microbiota is tested at times of mucosal injury when changes in immune activation and microbiota composition are likely to take place 80 . Given its vast surface area and constant exposure to the environment, the intestinal epithelial barrier is susceptible to damage by pathogens, ischaemia and environmental toxins. Numerous animal models of colitis have explored the diverse ways in which such insults lead to chronic inflammation in genetically predisposed animals, revealing complex immune-microbial interactions. Notably, although animal models have greatly advanced our understanding of IBD patho genesis, they have inherent limitations
. Nevertheless, these systems have enforced the notion of 'dysregulated' immunity as a key driver of IBD and have established diverse and context-dependent roles for the gut microbiota in health and disease. In the following sections the issue of causation versus correlation of dysbiosis will be considered in the context of specific IBD animal models.
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Chitin β-glucan A key feature of the adoptive transfer and TRUC models is their dependence on the microbiota, as germfree animals do not develop colitis. In the adoptive T-cell transfer model, several specific micro organisms have been implicated, including Helicobacter muridarum, Helicobacter hepaticus and segmented filamentous bacteria (SFB); however, in most cases, colonization with a defined cocktail of specific pathogen-free (SPF) bacteria is also required for colitis to develop [95] [96] [97] . Conversely, co-colonization with the human symbi ont Bacteroides fragil is reverses the inflammatory effects of Helicobacter hep aticus by promoting T reg -cell development 98, 99 . Similarly, Klebsiella pneumoniae and Proteus mirabilis cause colitis in TRUC mice, but only in the presence of the endogen ous microbiota 100 . Thus, the inflammatory potential of individ ual pathobionts is ultimately determined by the overall composition of the gut microbiota. Moreover, TRUC mice can transmit colitis even to wild-type animals, suggesting that the inflammatory environment can condition the gut microbiota to cause disease even in the absence of host risk factors 101 .
Regulatory T cells and immune tolerance.
T reg cells are a distinct subset of helper T cells defined by the transcription factor FOXP3 and anti-inflammatory cytokine IL-10. As with T H 17 cells, T reg cells are induced by transforming growth factor (TGF) β, accumulate at mucosal surfaces, and differentiate under the influence of commensal organisms and environmental signals 81, 102, 103 . In humans, mutations in FOXP3 lead to chronic enteritis 104 , whereas blockade of SMAD7, an inhibitor of TGFβ, improves inflammation by augmenting T reg -cell function 105, 106 . Similarly, IL10 polymorphisms have been associated with human IBD in GWAS, and congenital IL-10 deficiency leads to severe childhood colitis 107, 108 . Not surprisingly, spontaneous colitis in Il10 −/− mice depends on the gut microbiota and is driven by unopposed T H 17 cells 109, 110 . Conversely, specific microbial species -including Bacteroides fragilis 98, 99 and a consortium of human-derived Clostridia strains 111 -can alleviate inflammation in several colitis models by promoting T reg -cell development (FIG. 2) . Thus, the relative abundance of T H 17 and T reg cells is a key factor in determining intestinal inflammation versus tolerance. By differentially promoting the development of these immune subsets, the gut microbiota have an important role in maintaining or disrupting intestinal homeostasis.
Microbial sensing, the inflammasome and epithelial repair. The complex relationship between the gut microbiota and intestinal inflammation is further illustrated by innate models of colitis. Innate immune cells detect pathogenic and commensal bacteria via a conserved set of pattern-recognition receptors that are linked to NF-κB activation, inflammasome assembly, and epithelial repair pathways (FIG. 2) . A number of these receptors -most notably NOD2, NLRP3, and several Toll-like receptors (TLRs) -have been implicated in the pathogenesis of IBD by GWAS [112] [113] [114] [115] [116] [117] [118] . Animal models involving NOD-like receptor (NLR) or TLR signalling defects have revealed a complex and contextdependent role of innate immunity in colitis, ranging from protective to pro-inflammatory.
MYD88 is a central adaptor for signalling through most TLRs, as well as the IL-1 and IL-18 receptors, and disruption of this protein leads to profound innate immune dysfunction 82 . Administration of DSS to Myd88 −/− mice results in severe and lethal colitis which, in contrast to the models discussed earlier, is not driven by the gut microbiota 82 . Thus, germ-free Myd88 −/− mice are not protected from DSS, and in fact antibiotic treatment of wild-type animals exacerbates disease severity 82 , consistent with a protective role for the gut microbiota. Indeed, bacterial sensing and signalling through TLRs is critical for epithelial repair by promoting secretion of tissue-protective factors, inhibiting apoptosis, and recruiting stromal and myeloid cells to the colonic crypts [119] [120] [121] [122] [123] [124] . Thus, the normal gut microbiota is essential for restoring homeostasis after acute mucosal injury.
A number of other mouse models have linked TLR and NLR signalling to epithelial repair and homeostasis after DSS injury. For example, absence of NF-κB activation in Nemo (also known as Ikbkg) −/− or Ikk1/2 (also known as Chuk-Ikbk) −/− mice results in spontaneous colitis characterized by increased epithelial apoptosis 125 . Similarly, inflammasome disruption via deletion of NLRP3 (linked to IBD in GWAS), NLRP6, PYCARD, caspase 1, or IL-18 leads to impaired epithelial repair and increased cancer susceptibility [126] [127] [128] [129] [130] . However, in most of these mouse models, defects in innate immunity also lead to the outgrowth and translocation of patho gens that contribute to the overall disease pheno type and respond to antibiotic treatment 125, 128 . For example, DSS colitis in NLRP6-deficient mice is complicated by the outgrowth of Prevotellaceae species, which can exacerbate disease when transferred to wild-type animals 130 . Similarly, Myd88 −/− mice develop severe colitis and 
Ileocolonic resection
Resection of the terminal ileum, caecum and ascending colon, followed by an ileocolonic anastomosis.
Ileostomy
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bacteraemia when colonized with the patho gen Citrobacter rodentium 131, 132 (FIG. 2) . Thus, sensing of the gut microbiota by innate immune cells maintains intestinal homeostasis by both limiting bacterial growth and promoting epithelial repair.
Paneth cells, autophagy and Crohn's ileitis.
Autophagy is a conserved process of targeted degradation of cytoplasmic pathogens and cellular components via the formation of a double-membrane vesicle 133 . This pathway has been implicated in the pathogenesis of Crohn's disease by GWAS, which have identified susceptibility loci in the ATG16L1 and IRGM autophagy genes 134, 135 . ATG16L1 has been linked to NOD2 activation 136, 137 and plays a key part in the function of Paneth cells, specialized epithelial cells located in the intestinal crypt base 138 . Paneth cells shape the gut microbiota via secretion of antimicrobial peptides 139 ; conversely, dysfunction of these cells has been associated with Crohn's disease 140 . Cadwell et al. 141 have shown that mice hypomorphic for ATG16L1 develop Paneth cell defects upon infection with a chronic strain of murine norovirus (MNV). Subsequent administration of DSS to such MNV-infected mice triggers Crohn's disease-like colonic lesions in a microbiotadependent manner. This model provides an elegant example of the convergence of genetic, environmental and microbial factors to produce the clinical phenotype of Crohn's disease.
Paneth cell dysfunction and dysbiosis have also been implicated in the TNF ΔARE model of Crohn's disease ileitis 142 . TNF ΔARE mice have dysregulated TNF expression due to deletions in the AU-rich elements (ARE) of Tnf, leading to chronic ileal inflammation 143 . Ileitis in conventionally reared TNF ΔARE mice is microbiotadependent and can be attenuated by antibiotic treatment. Remarkably, TNF ΔARE mice reared in an SPF environment, develop discrete gradients of disease activity ranging from normal to severe ileitis. These clinical pheno types correspond to distinct degrees of dysbiosis and Paneth cell dysfunction in individual mice. Moreover, the gut microbiota from inflamed, but not from healthy, TNF ΔARE mice can transmit ileitis and Paneth cell defects to germfree TNF ΔARE recipients, pointing to a direct causal relationship between dysbiosis and inflammation.
IgA-coated taxa in the gut microbiota as possible pathobionts in IBD. IgA is the predominant antibody isotype at mucosal surfaces and exerts protective and immunoregulatory effects by modulating the composition of the gut microbiota 144 . IgA coating of intestinal bacteria can distinguish colitogenic (IgA + ) from commensal (IgA − ) species, and IgA + bacteria identified in this manner include known pathobionts (Prevotellaceae, Helicobacter and SFB) capable of mediating DSS-induced colitis when transferred to SPF mice 145 . Moreover, IgA + bacteria isolated from patients with IBD, but not from healthy individuals, led to severe DSS-induced colitis when transferred to SPF mice 145 . A major feature that dis tinguished colitogenic IgA + from non-colitogenic IgA − bacteria was the ability of the former to penetrate the mucus layer and trigger T-cell-dependent high-affinity IgA production (FIG. 2) . Thus, identifying colitogenic bacteria based on IgA coating could eventually lead to a personalized treatment approach for IBD. These findings further suggest that IgA has an anti-inflammatory role by selectively neutralizing colitogenic bacteria. Consistent with this interpretation, IgA deficiency has been associ ated with a 3.9 and 5.7 prevalence ratio for ulcerative colitis and Crohn's disease, respectively 146 .
Human IBD: evidence from clinical studies As discussed in the preceding sections, dysbiosis in patients with IBD has been well-documented. Moreover, the microbiota have a variety of roles in IBD models of intestinal inflammation, ranging from protective to causative. As many such models have been informed by GWAS data and are based on knockouts of human suscepti bility genes, one might speculate that bacteria, fungi and viruses have similar roles in human IBD. However, as discussed in BOXES 1,2, results from animal studies have a number of limitations and must be interpre ted with caution, especially with regards to their relevance to human disease. The question of whether dysbiosis precedes the development of IBD and sets the inflammatory process in motion, or merely reflects the altered immune and metabolic environment of the inflamed mucosa, remains to be answered. Although a number of human participant studies support a causal role of dys biosis in IBD pathogenesis, conclusions are limited by the lack of prospective data.
IBD preferentially affects intestinal regions with the highest abundance of bacteria, and both faecal diversion and antibiotics can be effective in the management of Crohn's disease [10] [11] [12] . Individuals with active Crohn's disease who undergo ileocolonic resection and placement of a diverting ileostomy often have a normal neoterminal ileum 3-6 months after surgery 11, 147 . Moreover, infusion of the proximal ileum effluent into the excluded distal ileum can lead to disease recurrence, although the precise factor(s) mediating inflammation have not been determined 147 . Of note, faecal stream diversion is not universally effective and can itself be colitogenic by depriving colonocytes of SCFAs normally produced by resident bacteria 148 . The possibility that inflammation in IBD might be driven by the gut microbiota has informed a number of clin ical approaches aimed at correcting dysbiosis by dietary or microbial interventions. Examples include the use of probiotics, antibiotics, defined enteral nutritional therapy (ENT), and faecal microbiota transplantation (FMT). Probiotics are mixtures of bacteria or yeasts with perceived beneficial health effects, utilized to restore gut microbial balance 149 . To date, evidence for the efficacy of probiotics in the treatment of IBD is equivocal 149 . The most compelling findings come from post-surgical patients with ulcerative colitis who have undergone ileal pouch-anal anastomosis. Such patients are predisposed to inflammation of the ileal pouch (pouchitis) and probiotics have been shown to be effective in preventing this complication following successful antibiotic treatment 149, 150 . However, basic questions regarding the optimal composition of probiotics, timing of administration and durability of the response remain unanswered. . Moreover, several studies have shown that broad-spectrum antibiotics improved rates of steroid-free remission in ulcerative colitis [151] [152] [153] . Given the phenotypic heterogeneity of IBD and the diversity of human populations, it is not surprising that inconsistent outcomes of antibiotic treatment have been reported. Indiscriminately targeting the gut microbiota with broad-spectrum antibiotics probably depletes beneficial, as well as pathogenic, microorganisms with potentially unpredictable consequences. As with probiotics, future antibiotic regimens might have to be tailored to individual patients based on their specific gut microbiota composition and genetic makeup.
Diet has been shown to have a major effect on the composition of the gut microbiota by altering its functionality and metabolism at the genomic level 154 . Epidemiological evidence points to a role of diet in the pathogenesis of IBD, and dietary modification has long been used as therapy for Crohn's disease 155 . ENT with elemental, semi-elemental, or polymeric formulas can be used as first-line therapy for the induction of remission in Crohn's disease and has been associated with both clinical improvement and mucosal healing [156] [157] [158] [159] [160] [161] . Although the mechanism of action of ENT has not been well defined, hypotheses include reduction in luminal antigens second ary to food exclusion and/or modulation of the gut microbiota and its metabolome. Several studies have shown a change in faecal microbiota composition following ENT therapy 37, 162, 163 , as well as functional changes leading to increased levels of anti-inflammatory SCFAs in children with Crohn's disease 164 . ENT was effective in inducing remission in paediatric patients with Crohn's disease, and was associated with rapid changes in gut microbiota composition 37 . Another study further showed that ENT was associated with reduced numbers of T reg cells in the lamina propria, reflecting the resolution of intestinal inflammation 165 . Notably, favourable therapeutic outcomes of ENT that we and others have reported was associated with initial shifts in microbial composition towards even greater dysbiosis relative to healthy individuals 37, 166 . These observations highlight the need to further explore the effects of diet on microbial composition and disease activity, and further point to the complex relationship between dysbiosis and IBD.
FMT has been explored as a strategy to correct dysbiosis. The success of FMT for the treatment of refractory Clostridium difficile infection 167 has generated strong interest in using this approach in IBD. However, clinical results so far have been varied, possibly reflecting the higher complexity of IBD compared to C. difficile colitis [168] [169] [170] [171] . Two randomized, placebo-controlled trials for the treatment of ulcerative colitis showed that FMT was markedly more effective than placebo in inducing clinical and endoscopic remission in ulcerative colitis in adults 172, 173 . However, one other recent randomized, placebo-controlled trail failed to show a similar benefit of FMT 174 . Even fewer studies have explored FMT for the treatment of Crohn's disease and no randomizedcontrolled clinical trials have yet been completed although several are ongoing 175, 176 . In children, FMT has shown clinical benefit in a small cohort of patients with Crohn's disease 177 , whereas a pilot study of FMT in adult refractory Crohn's disease resulted in high rates of clinical remission and clinical improvement 178 . Overall, data regarding FMT are scarce and questions remain regarding the safety and durability of this approach (short-term and long-term), particularly in immunosuppressed patients; the most effective mode of administration; and how to select appropriate donors and recipients. Larger randomized controlled trials are necessary to better define the role of FMT in the treatment of IBD.
Conclusions
In this Review, we have summarized human micro biome and metabolome associations with IBD, provided an overview of animal models with a focus on host-microbial interactions and their effect on mucosal homeostasis, and discussed the potential therapeutic role of the gut microbiota in IBD management. Our analysis seems to suggest a greater effect of the gut microbiota on disease phenotype and activity in mice than in humans receiving microbial-based therapies. What is the basis for this difference? One interpretation is that the micro biota plays, at most, a limited part in the pathogenesis of human IBD and dysbiosis is simply a marker of disease
. Such a conclusion is supported by a longitu dinal analysis published in 2017 of faecal microbiota from patients with IBD, which failed to show a correlation between the degree of dysbiosis and Crohn's disease severity 24 . It should be noted, however, that the authors used faecal calprotectin levels as a marker of disease activity and, therefore, might have underestimated the severity of ileal inflammation. In fact, the same study showed that recent steroid use (which probably reflected disease exacer bation) did correlate with increased microbiome instability. Similarly, a study of paediatric patients with IBD showed a significant correlation between microbota composition and disease severity, with resolution of dysbiosis in patients responding to anit-TNF therapy 179 . Nevertheless, a clear causeeffect relationship between dysbiosis and human IBD reamins to be definitively established.
We believe in a nuanced interpretation of the differences between mouse and human studies. First, responses to the gut microbiota are likely to differ between mammalian species. Second, mice are genetically homogenous, consume a monotonous diet, and inhabit a well-defined environment, in which the microbiota is shared between co-housed cagemates through coprophagia. The latter observation probably accounts for the substantial 'cage effects' observed in microbiome studies 180 . Third, similari ties between mice are amplified further in germ-free or gnotobiotic studies in which even fewer differences are present between individual animals. This uniformity contributes to a high signal-to-noise ratio and enables investigators to observe reproducible outcomes with relatively low numbers of experimental animals. Such tightly controlled experimental conditions have been critical in establishing cause-effect relationships and uncovering novel biological responses and pathways.
By contrast, humans live in a highly variable environment, exhibit genetic diversity, and consume a variable diet. This inherent variability is even more pronounced in IBD in which disease activity, medication use, and numerous environmental factors such as smoking can modulate the individual response to the gut microbiota and their metabolites. Indeed, intersubject variability is often one of the largest sources of variance in human gut microbiome studies, leading to a low signal-to-noise ratio that can obscure meaningful biological outcomes. Thus, one of the lessons learned from microbiota-based interventional studies in humans might be that such approaches show a hint of promise but will require further adjustment to amplify the favourable clinical response above the threshold of normal human variation. To address these issues, there is a need for large prospective longitudinal studies such as the Genetic Environmental Microbial (GEM) Project to define interactions between human genetics, environmental factors, and microbial composition that contribute to the development of IBD 181 .
It is important to recognize that the relationship between dysbiosis and IBD is probably complex and dynamic, rather than one of simple cause-effect. Thus, the view of dysbiosis as the response of a complex microbial community to the environmental stress of inflammation or medication use is not incompatible with the notion that dysbiosis plays a direct role in IBD pathogenesis. For example, dysbiosis might not be the inciting event but might develop later in the course of IBD and contribute to disease progression and chronicity. Studies of next-generation probiotics and larger controlled FMT trials could provide proof-of-concept in support of this notion.
Alternatively, it is possible that the gut micro biota have a critical role in the initiation of disease but that the window for such an effect occurs early in life. Concurrent with industrialization, the incidence of Crohn's disease and ulcerative colitis has risen globally, revealing a number of important associations between early life exposures and IBD 13 . Thus, birth by caesarean section, childhood exposure to antibiotics, use of infant formula, and residence in a sanitized environment have emerged as risk factors for the development of IBD and other immune-mediated diseases 13 . Conversely, childhood exposure to house dust in a rural setting is protective against the development of asthma, providing a cogent example of this principal 182 . Moreover, mouse models in which the gut microbiota are altered in early life phenocopy the associations with diseases observed in humans 183, 184 . Although it might be difficult to demonstrate efficacy of a microbiota-based strategy for disease prevention, such an approach could be enourmously impactful, making it worth the investment in time, energy and resources.
In conclusion, we believe that association studies, animal models and early therapeutic trials collectively point to an important role of the gut microbiota and their metabolites in IBD pathogenesis. Translating these insights into viable therapeutic approaches might be challenging and require an investment in human subject research to definitively demonstrate cause-effect relation ships. Nevertheless, given the growing incidence of IBD worldwide and its association with environmental triggers, research into the gut microbiota with an eye towards therapeutics will be critically important.
